KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$71.8 million.

  • Xenon Pharmaceuticals' Cash from Operations fell 4447.2% to -$71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$252.0 million, marking a year-over-year decrease of 5518.12%. This contributed to the annual value of -$181.4 million for FY2024, which is 2003.61% down from last year.
  • Xenon Pharmaceuticals' Cash from Operations amounted to -$71.8 million in Q3 2025, which was down 4447.2% from -$64.2 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Cash from Operations high stood at -$13.1 million for Q2 2021, and its period low was -$71.8 million during Q3 2025.
  • For the 5-year period, Xenon Pharmaceuticals' Cash from Operations averaged around -$36.9 million, with its median value being -$34.4 million (2023).
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 1101.02% in 2022, then tumbled by 10619.22% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Cash from Operations (Quarter) stood at -$20.7 million in 2021, then tumbled by 70.59% to -$35.3 million in 2022, then fell by 0.2% to -$35.4 million in 2023, then crashed by 53.63% to -$54.4 million in 2024, then tumbled by 31.93% to -$71.8 million in 2025.
  • Its Cash from Operations was -$71.8 million in Q3 2025, compared to -$64.2 million in Q2 2025 and -$61.7 million in Q1 2025.